The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The approval is for Cytomegalovirus, a type of Herpes virus
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Subscribe To Our Newsletter & Stay Updated
